- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02474537
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function
This is a phase I, multi-center, open-label, single oral dose, parallel group study to evaluate the pharmacokinetics and safety of INC280 in non-cancer subjects with impaired hepatic function and non-cancer subjects with normal hepatic function.The study population will be healthy male and postmenopausal or sterile female subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will be assigned to groups according to their hepatic function: normal (Group 1), mild (Group 2), moderate (Group 3), and severe (Group 4) impairment. This study consists of a two-staged design with interim analysis. In Stage 1, subjects in Groups 1, 2 and 3 will be enrolled. Upon completion of Stage 1, an interim analysis will be conducted. Depending on the results of the analysis, either the study will conclude with no further enrollment or Stage 2 will commence with enrollment of Group 4.
A minimum of 6 evaluable subjects per group will be enrolled.Once enrolled in the study, participants will be confined to the facility for 4 days, given a single dose of INC280 and monitored for pharmacokinetic and safety assessments.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine Clinical Resea Oncology
-
Miami, Florida, Forente stater, 33142
- Clinical Pharmacology of Miami, LLC.
-
Orlando, Florida, Forente stater, 32086
- Orlando Clinical Research Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Davita Clinical Research
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center Oncology
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria (all groups):
- Female subjects must be postmenopausal or sterile
- Good health, as determined by absence of clinically significant findings in medical history, physical examination, vital signs, and ECGs, unless it is consistent with known clinical disease for hepatic impairment subjects
- Adequate organ function and normal laboratory tests, unless it is consistent with known clinical disease for hepatic impairment subjects
- Body Mass Index (BMI) of 18- 36 kg/m2, with body weight ≥ 50 kg
Inclusion Criteria (hepatic impairment groups):
- Confirmed liver disease
- Stable comorbidities are allowed as long as generally considered healthy
- Subjects with hepatic impairment must meet the following laboratory values:
- Aspartate transaminase (AST) ≤ 5 x ULN
- Alanine transaminase (ALT) ≤ 5 x ULN
- Total bilirubin ≤ 3 x ULN (≤ 5 x XULN for subjects with severe hepatic impairment [group 4])
- Calculated creatinine clearance (using Cockcroft-Gault formula) ≥ 45 mL/min
- Platelets > 50 x 10^9/L. Subjects with severe hepatic impairment can be enrolled if platelet count > 40 x 10^9/L
Exclusion Criteria (all groups):
- History or presence of clinically significant ECG abnormalities or clinically significant cardiovascular disease
- Immunocompromised subjects, including HIV
- Use of drugs known to affect CYP3A4
- Use of QT-prolonging drugs
- Use of any other drugs, unless they are required to treat the hepatic impairment subject's disease
- Use of proton pump inhibitors (PPI) medications within 7 days prior to dosing and during the current study until last day of confinement
Exclusion Criteria (normal hepatic function group):
- A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result
Exclusion Criteria (hepatic impairment groups):
- Active Grade 3 or 4 hepatic encephalopathy within 4 weeks of study entry
- Clinical evidence of severe ascites
- Ascites requiring paracentesis within 3 weeks prior to dosing
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Normal leverfunksjon
Personer med normal leverfunksjon
|
Single 200 mg dose INC280
|
Eksperimentell: Lett nedsatt leverfunksjon
Personer med lett nedsatt leverfunksjon
|
Single 200 mg dose INC280
|
Eksperimentell: Moderat nedsatt leverfunksjon
Personer med moderat nedsatt leverfunksjon
|
Single 200 mg dose INC280
|
Eksperimentell: Severe hepatic impairment
Subjects with severe hepatic impairment
|
Single 200 mg dose INC280
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
AUClast of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
AUCinf of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
Cmax of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
Tmax of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
T1/2 of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
CL/F of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
Vz/F of INC280
Tidsramme: Up to 72 hours post-dose
|
INC280 pharmacokinetic parameters
|
Up to 72 hours post-dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Adverse events based on the CTCAE v4.03 grade (severity) and frequency, and other safety data (e.g., ECG, laboratory results)
Tidsramme: Up to 30 days
|
Safety
|
Up to 30 days
|
Unbound fraction and AUClast based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and AUCinf based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and Cmax based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and Tmax based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and T1/2 based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and CL/F based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Unbound fraction and Vz/F based on unbound concentration in plasma
Tidsramme: 3 hours post-dose
|
To assess the plasma protein binding of INC280
|
3 hours post-dose
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: NovartisPharmaceuticals, NovartisPharmaceuticals
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CINC280A2106
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nedsatt leverfunksjon
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RekrutteringSøvnforstyrrelser | AMCI - Amnestic Mild Cognitive ImpairmentForente stater
Kliniske studier på INC280
-
Novartis PharmaceuticalsFullførtSolide svulsterTyskland, Forente stater, Nederland, Spania, Canada, Hong Kong, Italia, Singapore, Australia, Israel, Korea, Republikken, Taiwan, Frankrike, Norge, Thailand
-
Novartis PharmaceuticalsAvsluttetAvansert hepatocellulært karsinom med c-MET-dysreguleringKina, Hong Kong, Thailand, Singapore
-
Novartis PharmaceuticalsFullførtcMET Dysegulation Advanced Solid TumorsØsterrike, Danmark, Sverige, Storbritannia, Spania, Tyskland, Nederland, Forente stater
-
Novartis PharmaceuticalsFullførtAvansert solid svulstJapan
-
Novartis PharmaceuticalsAvsluttetc-MET-hemmer; PI3K-hemmer, PTEN-mutasjoner, Homozygot Del. av PTEN eller PTEN Neg. av IHC, c-Met Ampli. av FISH, INC280, BKM120, Buparlisib; Tilbakevendende GBMSpania, Sveits, Tyskland, Forente stater, Nederland
-
Novartis PharmaceuticalsTilbaketrukketKarsinom | Ikke-småcellet lungekreft
-
Novartis PharmaceuticalsTilgjengeligIkke-småcellet lungekreft | Ikke-småcellet lungekreft | Karsinom, ikke-småcellet lunge | Ikke-småcellet lungekarsinom
-
Novartis PharmaceuticalsAktiv, ikke rekrutterendeIkke-småcellet lungekreftForente stater
-
Massachusetts General HospitalNovartisFullførtOndartet ikke-småcellet neoplasma i lungestadium IVForente stater
-
Novartis PharmaceuticalsAktiv, ikke rekrutterendeIkke-småcellet lungekreft (NSCLC)Kina